Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector

Human Gene Therapy

Volumn 11, Issue 6, 2000, Pages 859-868

  Maione, Domenico ^a   Wiznerowicz, Maciej ^b   Delmastro, Paola ^a   Cortese, Riccardo ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a   Savino, Rocco ^a  

^a IRBM   (Italy)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANEMIA; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE EXPRESSION; GENE THERAPY; HEMATOCRIT; MOUSE; NONHUMAN; RAT;

ADENOVIRIDAE; ANIMALS; ANTIBODY FORMATION; ERYTHROPOIETIN; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOCRIT; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SEQUENCE DELETION; SPECIES SPECIFICITY; TIME FACTORS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0034630303     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015473     Document Type: Article

References (52)

1. ADAMSON, J.W., and ESCHBACH, J.W. (1998). Erythropoietin for end-stage renal disease. N. Engl. J. Med. 339, 625-627.
2. ARIAS, I.M., BOYER, J.L., FAUSTO, N., JAKOBY, W.B., SCHACHTER, D.A., and SHAFRITZ, D.A. (1994). The Liver: Biology and Pathobiology , 3rd Ed. (Raven Press, New York).
3. BENDTZEN, K., HANSEN, M.B., ROSS, C., and SVENSON, M. (1998). High-avidity autoantibodies to cytokines. Immunol. Today 19, 209-211.
4. BOHL, D., NAFFAKH, N., and HEARD, J.M. (1997). Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nature Med. 3, 299-305.
5. BOHL, D., SALVETTI, A., MOULLIER, P., and HEARD, J.M. (1998). Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92, 1512-1517.
6. BURCIN, M.M., SCHIEDNER, G., KOCHANEK, S., TSAI, S.Y., and O'MALLEY, B.W. (1999). Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. U.S.A. 96, 355-360.
7. CHARTIER, C, DEGRYSE, E., GANTZER, M., DIETERLE, A., PAVIRANI, A., and MEHTALI, M. (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805-4810.
8. CHEN, H.H., MACK, L.M., KELLY, R., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1999). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U.S.A. 94, 1645-1650.
9. CLEMENS, P.R., KOCHANEK, S., SUNADA, Y., CHAN, S., CHEN, H.H., CAMPBELL, K.P., and CASKEY, C.T. (1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3, 965-972.
10. DESCAMPS, V., BLUMENFELD, N., VILLEVAL, J.L., VAINCHENKER, W., PERRICAUDET, M., and BEUZARD, Y. (1994). Erythropoietin gene transfer and expression in adult normal mice: Use of an adenovirus vector. Hum. Gene Ther. 5, 979-985.
11. FISHER, J.W. (1997). Erythropoietin: Physiologic and pharmacologic aspects. Proc. Soc. Exp. Biol. Med. 216, 358-369.
12. GAHERY-SEGARD, H., JUILLARD, V., GASTON, J., LENGAGNE, R., PAVIRANI, A., BOULANGER, P., and GUILLET, J.G. (1997). Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts. Eur. J. Immunol. 27, 653-659.
13. GUO, Z.S., WANG, L.-H., EISENSMITH, R.C., and WOO, S.L.C. (1996). Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther. 3, 802-810.
14. HAMAMORI, Y., SAMAL, B., TIAN, J., and KEDES, L. (1995). Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J. Clin. Invest. 95, 1808-1813.
15. HITT, M., BETT, A.J., ADDISON, C.L., PREVEC, L., and GRAHAM, F.L. (1995). Techniques for human adenovirus vector construction and characterization. In Methods in Molecular Genetics,Vol. 7. K.W. Adolph, ed. (Academic Press, San Diego, CA) pp. 13-30.
16. HUANG, S.N., and CHISARI, F.V. (1995). Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 21, 620-626.
17. JOOSS, K., TURKA, L.A., and WILSON, J.M. (1998). Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5, 309-319.
18. KAJIWARA, K., BYRNES, A.P., CHARLTON, H.M., WOOD, M.J., and WOOD, K.J. (1997). Immune responses to adenoviral vectors during gene transfer in the brain. Hum. Gene Ther. 8, 253-265.
19. KAPLAN, J.M., ARMENTANO, D., SPARER, T.E., WYNN, S.G., PETERSON, P.A., WADSWORTH, S.C., COUTURE, K.K., PENNINGTON, S.E., ST. GEORGE, J.A., GOODING, L.R., and SMITH, A.E. (1997). Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8, 45-56.
20. KESSLER, P.D., PODSAKOFF, G.M., CHEN, X., McQUISTON, S.A., COLOSI, P.C., MATELIS, L.A., KURTZMAN, G.J., and BYRNE, BJ. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93, 14082-14087.
21. KIM, D.W., UETSUKI, T., KAZIRO, Y., YAMAGUCHI, N., and SUGANO, S. (1990). Use of the strong human elongation factor 1α promoter as a versatile and efficient expression system. Gene 91, 217-223.
22. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
23. KRANTZ, S.B. (1991). Erythropoietin. Blood 77, 419-434.
24. KRUMWIEH, D., ARNOLD, I., and SEILER, F.R. (1988). Biological characterization of recombinant hum an erythropoietin. Behring Inst. Mitt. 83, 193-201.
25. LOCHMULLER, H., PETROF, B.J., PARI, G., LAROCHELLE, N., DODELET, V., WANG, Q., ALLEN, C., PRESCOTT, S., MASSIE, B., NALBANTOGLU, J., and KARPATI, G. (1996). Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther. 3, 706-716.
26. MASTRANGELI, A., HARVEY, B.G., YAO, J., WOLFE, G., KOVESDI, I., CRYSTAL, R.G., and FALCK-PEDERSEN, E. (1996). "Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus hum oral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-87.
27. MORRAL, N., PARKS, R.J., ZHOU, H., LANGSTON, C., SCHIEDNER, G., QUINONES, J., GRAHAM, F.L., KOCHANEK, S., and BEAUDET, A.L. (1998). High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alphal-antitrypsin with negligible toxicity. Hum. Gene Ther. 9, 2709-2716.
28. MORSY, M.A., GU, M., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLEN, H., FRANLIN, L., PARKS, R.J., GRAHAM F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
29. NAFFAKH, N., HENRI, A., VILLEVAL, J.L., ROUYER-FESSARD, P., MOULLIER, P., BLUMENFELD, N., DANOS, O., VAINCHENKER, W., HEARD, J.M., and BEUZARD, Y. (1995). Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92, 3194-3198.
30. OLIVIERI, N.F., FREEDMAN, M.H., PERRINE, S.P., DOVER, G.J., SHERIDAN, B., ESSENTINE, D.L., and NAGEL, R.L. (1992). Trial of recombinant human erythropoietin: Three patients with thalassemia intermedia. Blood 80, 3258-3260.
31. OSBORNE, W.R., RAMESH, N., LAU, S., CLOWES, M.M., DALE, D.C., and CLOWES, A.W. (1995). Gene therapy for long-term expression of erythropoietin in rats. Proc. Natl. Acad. Sci. U.S.A. 92, 8055-8058.
32. PAGANINI, E.P., and MILLER, T. (1993). Erythropoietin therapy in renal failure. Adv. Intern. Med. 38, 223-243.
33. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
34. RACHMILEWITZ, E.A., and AKER, M. (1998). The role of recombinant human erythropoietin in the treatment of thalassemia. Ann. N.Y. Acad. Sci. 850, 129-138.
35. RACHMILEWITZ, E.A., AKER, M., PERRY, D., and DOVER, G. (1995). Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. Br. J. Haematol. 90, 341-345.
36. RENDAHL, K.G., LEFF, S.E., OTTEN, G.R., SPRATT, S.K., BOHL, D., VAN ROEY, M., DONAHUE, B.A., COHEN, L.K., MANDEL, R.J., DANOS, O., and SNYDER, R.O. (1998). Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nature Biotechnol. 16, 757-761.
37. RINSCH, C., REGULIER, E., DEGLON, N., DALLE, B., BEUZARD, Y., and AEBISCHER, P. (1997). A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Hum. Gene Ther. 8, 1881-1889.
38. RIZZUTO, G., CAPPELLETTI, M., MAIONE, D., SAVINO, R., LAZZARO, D., COSTA, P., MATHIESEN, I., CORTESE, R., CILIBERTO, G., LAUFER, R., LA MONICA, N., and FATTORI, E. (1999). Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Natl. Acad. Sci. U.S.A. 96, 6417-6422.
39. RODGERS, G.P., DOVER, G.J., UYESAKA, N., NOGUCHI, C.T., SCHECHTER, A.N., and NIENHUIS, A.W. (1993). Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl. J. Med. 328, 73-80.
40. SAMULSKI, R.J., CHANG, L.S., and SHENK, T. (1987). A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61, 3096-3101.
41. SCHIEDNER, G., MORRAL, N., PARKS, R.J., WU, Y., KOOPMANS, S.C., LANGSTON, C., GRAHAM, F.L., BEAUDET, A.L., and KOCHANEK, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 18, 180-183.
42. SETOGUCHI, Y., DANEL, C., and CRYSTAL, R.G. (1994). Stimulation of erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 84, 2946-2953.
43. SHOEMAKER, C.B., and MITSOCK, L.D. (1986). Murine erythropoietin gene: Cloning, expression and human gene homology. Mol. Cell. Biol. 6, 849-858.
44. SNYDER, R.O., SPRATT, S.K., LAGARDE, C., BOHL, D., KASPAR, B., SLOAN, B., COHEN, L.K., and DANOS, O. (1997). Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8, 1891-1900.
45. SVENSSON, E.C., BLACK, H.B., DUGGER, D.L., TRIPATHY, S.K., GOLDWASSER, E., HAO, Z., CHU, L., and LEIDEN, J.M. (1997). Long-term erythropoietin expression in rodents and nonhuman primates following intramuscular injection of a replication-defective adenoviral vector. Hum. Gene Ther. 8, 1797-1806.
46. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
47. VISVADER, J.E., ELEFANTY, A.G., STRASSER, A., and ADAMS, J.M. (1992). GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO J. 11, 4557-4564.
48. WALTER, J., YOU, Q., HAGSTROM, J.N., SANDS, M., and HIGH, K.A. (1996). Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc. Natl. Acad. Sci. U.S.A. 93, 3056-3061.
49. + CTLs in vivo. J. Immunol. 155, 2564-2570.
50. YANG, Y., NUNES, F.A., BERENSCI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
51. YE, X., RIVERA, V.M., ZOLTICK, P., CERASOLI, F., JR., SCHNELL, M.A., GAO, G., HUGHES, J.V., GILMAN, M., and WILSON, J.M. (1999). Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283, 88-91.
52. ZHOU, S., MURPHY, J.E., ESCOBEDO, J.A., and DWARKI, V.J. (1998). Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of HCT in nonhuman primates. Gene Ther. 5, 665-670.